Question 1

Does Citadel Advisors own NBRV stock?

Accepted Answer

No. Citadel Advisors exited its NBRV (Nabriva Therapeutics) position in Q3 2022. Its Q2 2022 13F listed 178,794 shares worth $33,000.

Question 2

How many shares of NBRV does Citadel Advisors own?

Accepted Answer

None since Q3 2022, when Citadel Advisors exited the position. Its Q2 2022 13F listed 178,794 shares worth $33,000.

Question 3

What is Citadel Advisors' NBRV position worth?

Accepted Answer

Citadel Advisors' NBRV position was worth $33,000 in its Q2 2022 13F, before the exit in Q3 2022.

Question 4

Is Citadel Advisors buying or selling NBRV?

Accepted Answer

In Q3 2022, Citadel Advisors exited its entire NBRV position.

Question 5

When did Citadel Advisors first buy NBRV?

Accepted Answer

Citadel Advisors first reported NBRV in its Q4 2020 13F and listed it in 7 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2022-Q3 Latest	Exited	0	-100.0%	$0	0.0%	—	0
2022-Q2	Increased	178,794	+1320.9%	$33,000	0.0%	—	22
2022-Q1	Decreased	12,583	-41.1%	$5,000	0.0%	—	0
2021-Q4	Decreased	21,382	-70.3%	$13,000	0.0%	—	0
2021-Q3	Increased	71,877	+98.5%	$86,000	0.0%	—	23
2021-Q2	Decreased	36,213	-64.9%	$49,000	0.0%	—	0
2021-Q1	Increased	103,262	+445.3%	$171,000	0.0%	—	25
2020-Q4	New	18,936	-	$46,000	0.0%	—	31

NBRV8 quarters

NBRV
8 quarters